MAIA BIOTECHNOLOGY INC

Maia Biotechnology (MAIA) gains 1.79% as investors eye clinical milestones and potential upside within a 52‑week range, promising a margin of safety for oncology‑focused investors.

Maia Biotechnology’s share price lags despite a 1.79 % uptick: thin trading, steep monthly decline, and a 52‑week low raise caution for investors.

Maia Biotechnology (MAIA) jumps 4.67 % as its oncology pipeline gains traction, nearing its 200‑day average and outpacing peers—an enticing value play for investors.